Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an update.
RemeGen Co., Ltd. announced the results of its 2024 Annual General Meeting and the 2025 first class meetings for A and H shareholders. All proposed resolutions were passed, including the approval of the 2024 financial accounts, annual profit distribution plan, and re-appointment of accounting firms. Special resolutions such as the issuance of additional shares and amendments to the Articles of Association were also approved, indicating strong shareholder support for the company’s strategic initiatives.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company is primarily focused on the development and commercialization of innovative biologic drugs, with a market focus on addressing unmet medical needs in oncology and autoimmune diseases.
Average Trading Volume: 11,857,060
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.54B
For an in-depth examination of 9995 stock, go to TipRanks’ Overview page.